Figure 6. . Molecular structures of protease-targeted chimera molecules targeting HMGCR/H-PGDS/IRAK4/GSK-3β for treatment of cardiovascular/immune and neurodegenerative diseases (blue indicates the E3 ligase ligand CRBN; red indicates the target inhibitor).

GSK-3β: Glycogen synthase kinase-3β; HMGCR: HMG-CoA reductase; H-PGDS: Hematopoietic prostaglandin-D synthase; IRAK4: IL receptor-associated kinase 4.